alphaveLALPATHLAB₹1,912.00

Dr. Lal Path Labs Ltd.

₹ CrorePeersMETROPOLIS VIJAYA THYROCARE NATCOPHARM NEULANDLAB NH COHANCE SAILIFEMcap ₹32,045 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Returns
Return on Common Equity	18.97	22.08	19.86	19.86
Return on Assets	14.75	18.12	16.20	16.20
Return on Capital Employed	23.39	23.92	23.03	23.03
Return on Invested Capital	22.34	27.48	25.21	27.07
Margins
EBITDA Margin	27.36	28.26	28.32	28.98
Operating Margin	20.92	22.49	22.47	22.47
Incremental Operating Margin	—	37.44	22.26	—
Pretax Margin	22.70	25.38	24.22	24.79
Net Income Margin	16.27	20.00	18.45	18.90
Net Income to Common Margin	16.06	19.79	18.27	18.75
FCF Margin	21.46	20.92	16.73	16.73
Additional
Effective Tax Rate	28.33	21.21	23.81	23.78
Dvd Payout Ratio	55.53	42.12	43.66	—
Sustainable Growth Rate	8.44	12.78	11.19	19.86
Incremental Operating Margin %	37.44	22.26	35.50	—

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.